Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase NA 1Phase 1/2 1

Status

Completed 18Recruiting 7Unknown 5Terminated 4Active not recruiting 2Withdrawn 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5Observational 3

Sponsor

Cancer Type

Genitourinary 5

Conditions

Breast Neoplasms 1275Carcinoma, Non-Small-Cell Lung 783Neoplasms 767Colorectal Neoplasms 755Carcinoma, Hepatocellular 579Stomach Neoplasms 578Prostatic Neoplasms 501Lung Neoplasms 461Pancreatic Neoplasms 416Rectal Neoplasms 331Recurrence 312Neoplasm Metastasis 305Leukemia, Myeloid, Acute 289Multiple Myeloma 281Colonic Neoplasms 280Lymphoma 273Uterine Cervical Neoplasms 269Esophageal Neoplasms 267Ovarian Neoplasms 261Head and Neck Neoplasms 246Melanoma 240Precursor Cell Lymphoblastic Leukemia-Lymphoma 209Brain Neoplasms 195Lymphoma, Large B-Cell, Diffuse 184Nasopharyngeal Carcinoma 180Lymphoma, Non-Hodgkin 173Leukemia 173Liver Neoplasms 163Glioblastoma 158Urinary Bladder Neoplasms 153

Interventions

talazoparib 1gallium 68 PSMA-11 1Radiosurgery 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Unknown × Interventional × Prostate Cancer Metastatic × Clear all
NCT06251492 2024-02-20

Radiation and Adebrelimab in Prostate Cancer With Imaging-measurable Disease (RAPID)

Fudan University

Phase 2 Unknown
30 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT05627778 2022-11-28

68Ga-P15-041 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Prostate Bone Metastasis

Peking Union Medical College Hospital

Phase 1/2 Unknown
30 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT05078151 2021-10-14

iPROMET

Vall d'Hebron Institute of Oncology

Phase NA Unknown
69 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT04824937 2021-04-01

Telaglenastat + Talazoparib In Prostate Cancer

Massachusetts General Hospital

Phase 2 Unknown
30 enrolled
Genitourinary

Prostate Cancer Metastatic

NCT04603833 2021-02-21

A Study of SHR3680 in Combination With Docetaxel in the Treatment of mCRPC

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Unknown
150 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡